[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Integrative Skin Science and Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,74,106,132,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636048","phase-4-obtaining-descriptive-classifications-of-pruritus-and-assessing-change-in-pruritus-over-time-in-atopic-dermatitis-patients-using-topical-roflumilast-cream-100636048",false,"NCT07560618","Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.","A Phase 4, Open Label Study to Assess Descriptive Classification of Pruritus Over Time With Roflumilast 0.15% Cream in Patients With Atopic Dermatitis","Inclusion Criteria:\n\n1. Male or female subjects aged 12 years or older\n2. Participants and\u002For legal guardians are legally competent to sign and give informed consent.\n3. Clinically confirmed diagnosis of active mild to moderate AD according to Hanifin and Rajka criteria (1980).\n4. History of AD for at least 6 months as determined by the Investigator using information from the subject's medical chart, from the subject's physician, or through subject\u002Fcaregiver interview. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening\n5. At least 3 months of chronic pruritus related to AD before the screening visit.\n6. EASI Score ≥5 at Baseline. EASI is evaluated for the entire body except the scalp, palms, and soles.\n7. vIGA-AD score of 'Mild' (2') or 'Moderate' (3') at Baseline. The vIGA-AD is evaluated for the entire body except the scalp, palms, and soles.\n8. Has AD involvement of ≥3% BSA (excluding the scalp, palms, soles) at Baseline.\n9. Participants must have access to a device and be willing to download the ExpiWell app and able to complete the associated questionnaires once daily at approximately the same time each day throughout participation in the study.\n10. Prior to the first application of study drug, participant has a baseline WI-NRS (24-hour recall period) and mItch-NRS score ≥ 4.0.\n11. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening and Baseline\u002FDay 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial. The use of abstinence as a contraceptive measure is acceptable if this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.\n12. Females of non-childbearing potential should be post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status should be confirmed with FSH testing) or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).\n13. In good health as judged by the Investigator, based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)\u002Flegal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.\n2. Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments.\n3. Participant had significant flares or unstable course in AD (i.e., condition worsened significantly or required significant change in medications, as per medical judgment) in the previous 4 weeks before screening or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.\n4. Participant has significant active systemic or localized infection, like clinically infected AD, or has used antibiotics (systemic or topical), antifungal or antiviral agents within 2 weeks prior to the run-in period.\n5. Participant with a history or presence of a condition that, in the opinion of the investigator, would interfere with the study assessments (e.g., generalized erythroderma, Netherton syndrome, psoriasis, or any skin condition other than AD that may risk inducing a pruritus flare\u002Fworsening).\n6. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline\u002FDay 1 and during the study.\n7. Participants have tattoos, scratches, open sores, excessive hair, or skin damage that, in the opinion of the investigator, may interfere with study evaluations.\n8. Subjects with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.\n9. Known allergies to roflumilast or to the excipients in Roflumilast cream (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphase and ceteth-10 phosphate).\n10. Participant has a clearly defined etiology for pruritus other than AD, including but not limited to urticaria, psoriasis, or other nonatopic dermatologic conditions; hepatic or renal disease; psychogenic pruritus; drug reaction; uncontrolled hyperthyroidism; and infection.\n11. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline\u002F Day 1.\n12. History of severe depression, suicidal ideation or behavior at Baseline\u002FScreening indicative of suicidal ideation or behavior, whether lifetime or recent\u002Fcurrent.\n13. Subjects currently undergoing allergy testing (eg, food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study.\n14. Subjects with any serious medical condition (eg, uncontrolled hypo- or hyper-thyroidism) or clinically significant laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.\n15. Previous treatment with Roflumilast cream or foam (any potency) or current Roflumilast use for any indication at the baseline visit that would be expected to continue during the trial.\n16. Subjects with a history of major surgery within 4 weeks prior to Baseline\u002FDay 1 or subjects who have major surgery planned during the study.\n17. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.\n18. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.\n19. Subjects with known or suspected severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C) as determined by the clinical investigator based upon subject's medical history and physical exam.","ALL","12 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.",[26,27],"ITCH","Atopic Dermatitis",[29,30,31,27,32],"Eczema","Itch","Pruritus","Topical","NOT_YET_RECRUITING","2026-04-23",{"date":36,"type":37},"2026-05-01","ACTUAL",{"date":39,"type":20},"2026-04",{"date":41,"type":20},"2027-08",{"name":43,"class":44},"Integrative Skin Science and Research","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100634789","phase-4-comparing-sarecycline-and-doxycycline-effects-on-the-skin-and-gut-bacteria-in-acne-100634789","NCT07544251","Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.","The Effects of Sarecycline Versus Doxycycline on the Gut Microbiome and Skin Microbiome in Acne.","Inclusion Criteria:\n\n1\\) Diagnosis of acne vulgaris with:\n\n* At least 10 inflammatory lesions (papules, pustules, and nodules) up to 100 noninflammatory lesions (open and closed comedones)\n* No more than 2 nodules on the face\n\nExclusion Criteria:\n\n1. Dermatological condition of face or facial hair that could interfere with clinical evaluations\n2. Subjects who have used the following medications (topical refers only to the facial area) will not be eligible:\n\n2a) Within 2 week prior to randomization:\n\n* Topical acne medications such as retinoids, antibiotics, hormonal modulators\n* Topical benzoyl peroxide\n* Topical anti-inflammatories and corticosteroids\n\n  2b) Within 4 weeks prior to randomization:\n* Systemic antibiotics\n* Systemic acne treatments\n* Oral probiotic supplement\n* Systemic corticosteroids\n\n  2c) Within 12 weeks prior to randomization:\n* Systemic retinoids\n\n  3\\) Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.\n\n  4\\) Individuals who are pregnant or breastfeeding.\n\n  5\\) Individuals on oral contraceptive pills or progesterone or estrogen containing therapies unless they have been on a stable dose for 2 months.\n\n  6\\) Individuals on finasteride or dutasteride\n\n  7\\) Current tobacco smoker or a tobacco smoking history that is greater than 5 pack-years.",true,"9 Years",{"count":56,"type":20},30,[23],"This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on the skin will be studied to see how each treatment may affect them and whether they change the profile of the bacteria that is present.",[60],"Acne Vulgaris",[60,62,63,64],"Sarecycline","Doxycycline","Microbiome","RECRUITING","2026-04-15",{"date":68,"type":37},"2026-04-22",{"date":70,"type":20},"2026-04-20",{"date":72,"type":20},"2027-06",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":53,"sex":81,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100560021","the-effects-of-topical-almond-oil-and-tretinoin-on-facial-wrinkles-100560021","NCT06571721","The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles","Prospective, Double-Blinded, Randomized Study of Topical Almond Oil and Tretinoin on Facial Wrinkles","Inclusion Criteria:\n\n* Post-menopausal women of Fitzpatrick skin types 1, 2, and 3\n* Individuals with facial fine lines and wrinkles\n\nExclusion Criteria:\n\n* Individuals who are pregnant or breastfeeding\n* Prisoners\n* Adults unable to consent\n* Those with a nut allergy or tocopherol allergy\n* Current smokers, those that have smoked within the past year, and former smokers with greater than a 10-pack- year history of smoking\n* Those with an autoimmune photosensitive condition or a known genetic condition with a deficiency in collagen production (such as Ehlers-Danlos syndromes)\n* Those who have undergone any cosmetic procedures to the face in the 3 months prior to enrollment in the opinion of the investigator. People that have undergone deeper chemical peels (TCA based peels) within 1 year prior to enrollment\n* Individuals who are unwilling to discontinue vitamin E containing supplements and food sources such as all nuts, sunflower seeds or sunflower oil during the washout and intervention\n* Individual who are unwilling to discontinue topical cosmetic products during the duration of the study or unwilling to undergo a 2-week washout of topicals that are known to modulate collagen and pigment:\n* Retinoids such as tretinoin, adapalene, retinol, except as provided by the study.\n* Antioxidant ingredients such as vitamin C or vitamin E.\n* Pigment reducing agents such as hydroquinone, azelaic acid, kojic acid, or a retinoid except for the retinol that is provided in this study.\n* Topicals that contain a nut oil or nut extract as part of their ingredient list.","FEMALE","18 Years",{"count":84,"type":20},90,[86],"NA","Investigate the topical use of almond oil, almond oil augmented with 0.5% vitamin E, 0.025% tretinoin oil augmented with castor oil on the appearance of facial fine lines and wrinkles, pigmentation, hydration, trans-epidermal water loss, and sebum excretion rate.",[89,90,91,92,93],"Collagen Degeneration","Wrinkle","Pigmentation","Elastic Skin","Sebum Deficiency",[95,96,97,91],"Facial Wrinkles","Skin biophysical properties","Photoaging","2024-08-26",{"date":100,"type":37},"2024-08-28",{"date":102,"type":37},"2024-07-22",{"date":104,"type":20},"2025-07-22",{"name":43,"class":44},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":53,"sex":16,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100521628","effects-of-oral-supplement-containing-l-histidine-and-antioxidants-on-the-skin-barrier-function-and-systemic-inflammation-in-rosacea-100521628","NCT06072066","Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","The Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","Inclusion Criteria:\n\n* Males and females 30 to 70 years of age\n* The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)\n* High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg\u002FL\n\nExclusion Criteria:\n\n* The presence of severe rosacea as noted by the investigator global assessment.\n* Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.\n* Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment\n* Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.\n* Those who are unwilling to keep their facial regimen the same throughout the study.\n* Individuals who have been on an oral antibiotic within the previous one month.\n* Individuals who are pregnant or breastfeeding.\n* Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.\n* Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.\n* Use of isotretinoin within the three months prior to enrollment.\n* Individuals on finasteride or dutasteride\n* Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.","30 Years","70 Years",{"count":116,"type":20},24,[86],"The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.",[120,121],"Rosacea","Systemic Inflammation",[120,123,124],"L-Histidine","Antioxidants",{"date":126,"type":37},"2024-08-27",{"date":128,"type":37},"2023-11-22",{"date":130,"type":20},"2024-12-31",{"name":43,"class":44},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":53,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":139,"type":20},150,[86],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[143,144,120,145],"Acne","Melasma","Seborrheic Dermatitis",[147,148],"Artificial Intelligent","Skin",{"date":126,"type":37},{"date":151,"type":37},"2023-06-06",{"date":153,"type":20},"2025-02-28",{"name":43,"class":44},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":53,"sex":81,"minAge":162,"maxAge":114,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":45},"100521798","the-effects-of-almond-on-facial-skin-collagen-and-wrinkles-100521798","NCT06074276","The Effects of Almond on Facial Skin Collagen and Wrinkles","Prospective Randomized Controlled Trial on the Effects of Almond on Facial Skin Collagen and Wrinkles","Inclusion Criteria:\n\n* Subjects 35 to 70 years of age of all skin types\n* 50% of the subjects will be postmenopausal women determined as \\>1-year loss of menstrual period\n* 50% of the subjects will be premenopausal women\n* BMI 18.5 - 35 kg\u002Fm2\n* Individuals with a habitual diet that has been maintained for at least 6 months and to be maintained for the duration of the study\n* Individuals must maintain their usual skincare products, defined as products that has been used for at least 1 month, for the duration of the study\n\nExclusion Criteria:\n\n* Those with a nut allergy\n* Those who are unwilling to discontinue oral collagen supplementation 1 month prior to the start of the study\n* Individuals who are unwilling to discontinue vitamin E or nut containing supplements 2 weeks prior to and during the intervention.\n* Individuals who are pregnant or breastfeeding\n* Change in skincare products during the study\n* Had a medical or cosmetic procedure such as laser resurfacing or plastic surgery to the face within the last 6 months (include botulinum toxin, dermal fillers, collagen, or other similar cosmetic procedure)\n* Has an autoimmune photosensitive condition or known genetic condition with a deficiency in collagen production (such as Ehler-Danlos)\n* Those with a skin disease on their face that would affect the assessment of their skin based on the assessment of the investigator.\n* Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years","35 Years",{"count":164,"type":20},60,[86],"Investigate the effects of almond consumption on collagen production, elastin levels, wrinkles, and pigmentation among premenopausal women and postmenopausal women belonging to all Fitzpatrick skin types.",[89,90,91,92],"2024-06-15",{"date":170,"type":37},"2024-06-18",{"date":172,"type":37},"2023-10-04",{"date":130,"type":20},{"name":43,"class":44},""]